Syros Pharmaceuticals
Syros Pharmaceuticals develops innovative treatments for hematologic malignancies, including tamibarotene for HR-MDS and AML, and SY-5609 for pancreatic cancer.
Company Overview
Syros Pharmaceuticals is headquartered at 35 CambridgePark Drive, 4th Floor, Cambridge, MA 02140. The company is dedicated to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Syros is motivated to help patients with blood disorders that have largely eluded targeted approaches. One of Syros' unique strategies involves their gene control platform, which systematically analyzes regulatory regions of the genome to identify disease-causing alterations in gene expression.
Products
Syros Pharmaceuticals focuses on developing small molecule drugs aimed at certain cancers. Their key products include tamibarotene, an oral selective RARα agonist targeted for higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML). Tamibarotene is currently being investigated in a Phase 3 SELECT-MDS-1 trial and a randomized Phase 2 SELECT-AML-1 trial. SY-2101, a novel oral form of arsenic trioxide, is under development for patients with acute promyelocytic leukemia (APL). SY-5609, a highly selective and potent oral CDK7 inhibitor, has shown promise in treating pancreatic cancer through combination therapy.
Gene Control Platform
Syros Pharmaceuticals utilizes a gene control platform to systematically analyze regulatory regions of the genome. This platform plays a crucial role in identifying disease-causing alterations in gene expression, leading to the discovery of several targets for small molecule drug development. This innovative approach enables Syros to focus on creating therapies that address the root causes of certain cancers and blood disorders that have been challenging to treat with traditional methods.
Clinical Trials and Research
Syros Pharmaceuticals is actively involved in clinical trials to evaluate the efficacy and safety of their drug candidates. Tamibarotene is currently undergoing investigation in the Phase 3 SELECT-MDS-1 trial and the randomized Phase 2 SELECT-AML-1 trial. Additionally, SY-5609 has shown promising single-agent activity, including prolonged stable disease, tumor shrinkage, and tumor marker decreases across multiple tumor types. In combination with chemotherapy, SY-5609 achieved a confirmed partial response in a pancreatic cancer patient who was unresponsive to frontline therapy.
Partnerships and Licensing
Syros Pharmaceuticals holds exclusive development and commercial rights to tamibarotene for cancer indications in the Americas, Europe, Australia, and Israel. The company is exploring partnership opportunities to develop and commercialize tamibarotene outside the United States. Additionally, Syros is seeking out-license opportunities for further development of SY-5609, aiming to collaborate with other organizations to expand the reach and impact of their innovative therapies.